HCC | WEBCASTS

Beginning Date

11/15/2017

Ending Date

11/15/2018

0.5

credits

0.5

contact hours

Speakers

Nikolaos Pyrsopoulos, MD
Chief of Gastroenterology and Hepatology
Rutgers - NJMS
Newark, NJ

Webcasts

Webcast must be viewed in its entirety to claim credit.

Accredited by:

Provided by:

Supported by:

This program is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Target Audience

This educational program is targeted at hepatologists and oncologists and delivers an update on the treatment and management of unresectable HCC, with a focus on the role of systemic therapy and the management of adverse events in a multidisciplinary setting.

Educational Objectives

Upon completion of this activity, the participants should be better able to:

•	Explain data on the prevalence and consequences of HCC in the general and underserved and minority populations, e.g., the Asian and Hispanic communities
•	Describe examples of how adverse events would be effectively managed in the course of standard systemic therapy and tailored care for a given patient
•	Interpret the role and benefits of utilizing a multidisciplinary approach when treating and managing unresectable HCC
•	Critique and compare the clinical profile of current systemic therapies and that of investigational therapies/agents to treat HCC based on efficacy, safety and tolerability

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation (CLDF). The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest:

All faculty and staff involved in the planning or presentation of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. Charles Willis, Director of Continuing Education, consults for Pfizer, Inc.; John Bayliss, VP, Business Development, spouse is an employee of Amgen, Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation (CLDF) have no relationships to disclose.

The opinions expressed during the enduring material are those of the faculty and do not necessarily represent the views of the Annenberg Center for Health Sciences at Eisenhower. The information is presented for the purpose of advancing the attendees' professional development.

Learner Assurance Statement:

The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of prospective faculty members' significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.